埃索美拉唑和奥美拉唑治疗幽门螺杆菌相关性胃溃疡的临床疗效分析

Clinical Efficacy of Esomeprazole and Omeprazole in the Treatment of Helicobacter Pylori-associated Gastric Ulcer

目的研究幽门螺杆菌相关性胃溃疡患者采取奥美拉唑和埃索美拉唑治疗的价值。方法方便选取该院2016年7月—2017年10月纳入的120例幽门螺杆菌相关性胃溃疡患者,按照入院顺序分为两组各60例,研究组采取埃索美拉唑,对照组采取奥美拉唑,对比两组临床治疗结果。结果研究组总有效率95.00%较对照组81.67%高(χ~2=8.622,P<0.05);治疗前两组的腹痛、腹胀、胃灼热以及嗳气症状积分差异无统计学意义(t=0.487,0.466,1.140,0.932,P>0.05);治疗后研究组症状积分(1.6±0.5)分、(1.8±0.5)分、(1.3±0.4)分以及(1.5±0.4)分均低于对照组(2.8±0.9)分、(2.9±0.9)分、(2.0±0.6)分以及(2.3±0.7)分(t=9.028,8.276,7.519,7.686,P<0.05)。结论幽门螺杆菌相关性胃溃疡患者采取埃索美拉唑治疗效果显著,快速改善临床症状,促进溃疡愈合,为预后提供保障。

Objective This paper tries to study the clinical value of Esomeprazole or Omeprazole in Hp（Helicobacter pylori）-associated gastric ulcer. Methods 120 patients with Hp-associated gastric ulcer treated from July 2016 to October2017 in the hospital were convenient selected. The subjects were assigned to two groups according to the registration number, 60 cases each group. Patients took the Esomeprazole or Omeprazole, respectively. The therapeutic outcomes were recorded. Results The total effective rate of the study group was 95.00% higher than that of the control group（81.67%）（χ^2=8.622, P〈0.05）; there was no significant difference in abdominal pain, abdominal distension, heartburn, and hernia symptom scores between the two groups（t=0.487, 0.466, 1.140, 0.932, P〉.05）; After treatment, symptom scores（1.6±0.5）points,（1.8±0.5）points,（1.3±0.4）points, and（1.5±0.4） points were lower in the study group than in the control group（2.8±0.9）points,（2.9±0.9） points,（2.0 ±0.6） points, and（2.3 ±0.7）points（t =9.028,8.276,7.519,7.686, P〈0.05）. Conclusion The efficacy of esomeprazole in the treatment of Helicobacter pylori-associated gastric ulcer was significant. It quickly improved clinical symptoms and promoted ulcer healing to provide protection for the prognosis.